Advertisement

Drugs

, Volume 65, Supplement 1, pp 83–96 | Cite as

Potent Gastric Acid Inhibition in Helicobacter pylori Eradication

  • Javier P. Gisbert
Review Article

Abstract

At present, antisecretory drugs —foremost among them the proton pump inhibitors (PPIs) — represent a keystone in Helicobacter pylori eradication therapy. The present article shall first compare the role of PPIs as compared with histamine H2 receptor antagonists, both of them in the role of antibiotic-associated antisecretory therapy, and shall then address the contribution of each of the various PPIs that have been developed until the present time to the H. pylori eradication therapies. In summary, it may be concluded that PPIs are more effective overall than H2 receptor antagonists when the two groups of antisecretory drugs are given at the usual standard doses together with antibiotics with the intention of eradicating H. pylori infection. However, all PPIs (omeprazole, lansoprazole, pantoprazole, rabeprazole, and esomeprazole) are equivalent when given together with two antibiotics to cure the infection.

Keywords

Omeprazole Pylorus Infection Clarithromycin Lansoprazole Triple Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgement

Supported in part by a Grant from the Instituto de Salud Carlos III (C03/02).

References

  1. 1.
    Sainz R, Borda F, Dominguez E, et al. Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group. Rev Esp Enferm Dig 1999; 91: 777–84Google Scholar
  2. 2.
    Gisbert JP, Calvet X, Gomollon F, et al. Treatment for the eradication of Helicobacter pylori. Recommendations of the Spanish Consensus Conference. Med Clin (Barc) 2000; 114: 185–95Google Scholar
  3. 3.
    Gisbert JP, Pajares JM. Helicobacter pylori therapy: first-line options and rescue regimen. Dig Dis 2001; 19: 134–43PubMedCrossRefGoogle Scholar
  4. 4.
    Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer [see comments]. N Engl J Med 1993; 328: 308–12PubMedCrossRefGoogle Scholar
  5. 5.
    Goh KL, Parasakthi N, Chuah SY, et al. Combination amoxycillin and metronidazole with famotidine in the eradication of Helicobacter pylori — a randomized, double-blind comparison of a three times daily and twice daily regimen. Eur J Gastroenterol Hepatol 1997; 9: 1091–5PubMedCrossRefGoogle Scholar
  6. 6.
    Yousfi MM, El-Zimaity HM, Cole RA, et al. Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli’s triple therapy). Aliment Pharmacol Ther 1996; 10: 119–22PubMedCrossRefGoogle Scholar
  7. 7.
    Drake IM, Axon TT, Clarke AH. Ranitidine in a twice daily triple-therapy regimen for the eradication of Helicobacter pylori [see comments]. Eur J Gastroenterol Hepatol 1996; 8: 1169–73PubMedCrossRefGoogle Scholar
  8. 8.
    Breuer T, Kim JG, el-Zimaity HM, et al. Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea [published erratum in Aliment Pharmacol Ther 1999; 13:567]. Aliment Pharmacol Ther 1997; 11: 939–42PubMedCrossRefGoogle Scholar
  9. 9.
    Gschwantler M, Dragosics B, Wurzer H, et al. Eradication of Helicobacter pylori by a 1-week course of famotidine, amoxicillin and clarithromycin. Eur J Gastroenterol Hepatol 1998; 10: 579–82PubMedCrossRefGoogle Scholar
  10. 10.
    Hulten K, Jaup B, Stenquist B, et al. Combination treatment with ranitidine is highly efficient against Helico-bacter pylori despite negative impact of macrolide resistance. Helicobacter 1997; 2: 188–93PubMedCrossRefGoogle Scholar
  11. 11.
    Lo WC, Lin HJ, Wang K, et al. Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease. Chung Hua I Hsueh Tsa Chih (Taipei) 1997; 59: 171–6Google Scholar
  12. 12.
    Gotz JM, Veenendaal RA, Veselic M, et al. Triple therapy with ranitidine, clarithromycin, and metronidazole in the treatment of Helicobacter pylori. Scand J Gastroenterol Suppl 1995; 212: 34–7PubMedCrossRefGoogle Scholar
  13. 13.
    Labenz J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Pract Res Clin Gastro-enterol 2001; 15: 413–31CrossRefGoogle Scholar
  14. 14.
    Savarino V, Sandro Mela G, Zentilin P, et al. Acid inhibition and amoxicillin activity against Helicobacter pylori [Letter; comment]. Am J Gastroenterol 1993; 88: 1975–6PubMedGoogle Scholar
  15. 15.
    Sakaguchi M, Ashida K, Umegaki E, et al. Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine. J Clin Gastroenterol 1995; 20: S27–31PubMedCrossRefGoogle Scholar
  16. 16.
    Holtmann G, Layer P, Goebell H. Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons [see comments] Z Gastroenterol 1996; 34: 267–72Google Scholar
  17. 17.
    Gisbert JP, Khorrami S, Calvet X, et al. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists —their efficacy with antibiotics in Helico-bacter pylori eradication. Aliment Pharmacol Ther 2003; 18: 757–66PubMedCrossRefGoogle Scholar
  18. 18.
    Adamek RJ, Labenz J. Ranitidine/amoxicillin vs omeprazole/amoxicillin for cure of H. pylori-positive gastric ulcer: role of acid suppression. Gastroenterology 1995; 108: A44Google Scholar
  19. 19.
    Borody TJ, Andrews P, Fracchia G, et al. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 1995; 37: 477–81PubMedCrossRefGoogle Scholar
  20. 20.
    Cataldo MG, Brancato D, Donatelli M, et al. Treatment of patients with duodenal ulcer positive for Helicobacter pylori infection: ranitidine or omeprazole associated with colloidal bismuth subcitrate plus amoxicillin. Curr Ther Res 1996; 57: 168–74CrossRefGoogle Scholar
  21. 21.
    Ell C, Schoerner C, Solbach W, et al. The AMOR study: a randomized, double-blinded trial of omeprazole versus ranitidine together with amoxycillin and metronidazole for eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 2001; 13: 685–91PubMedCrossRefGoogle Scholar
  22. 22.
    Grigoriev PY, Zoseeva OV, Jakovenko AV, et al. Zantac (ranitidine) —antimicrobial therapy vs omeprazole —antimicrobial therapy for Helicobacter pylori (HP) associated peptic ulcer (PU). Am J Gastroenterol 1994; 89: 1392Google Scholar
  23. 23.
    Gschwantler M, Dragosics B, Schutze K, et al. Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori — a randomized, controlled trial. Aliment Pharmacol Ther 1999; 13: 1063–9PubMedCrossRefGoogle Scholar
  24. 24.
    Hsu CC, Chen JJ, Hu TH, et al. Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2001; 13: 921–6PubMedCrossRefGoogle Scholar
  25. 25.
    Lamouliatte H. Controlled study of omeprazole—amoxicillin—tinidazole vs. ranitidine—amoxicillin—tinidazole in Helicobacter pylori associated duodenal ulcers (DU), final and long-term results. Ital J Gastroenterol 1991; 23 Suppl 2: 9Google Scholar
  26. 26.
    Lazzaroni M, Bargiggia S, Porro GB. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobac-ter pylori-associated duodenal ulcer. Am J Gastroenterol 1997; 92: 649–52PubMedGoogle Scholar
  27. 27.
    Mosca S, Rocco VP, De Caprio M, et al. Comparison of two double therapies (nizatidine plus amoxicilline v/s omeprazole plus amoxicilline) in patients with Helicobacter pylori positive duodenal ulcer. Gut 1995; 37 Suppl 2: A226Google Scholar
  28. 28.
    Murakami K, Sato R, Kubota T, et al. Effects of new triple therapy regimens of inhibition of gastric acid secretion and eradication of Helicobacter pylori in a randomized trial. Gastroenterology 1999; 116: A260Google Scholar
  29. 29.
    Oderda G, Caristo P, Kuvidi M, et al. Evaluation of different treatment schedules in childhood Helicobacter pylori gastritis: a 10 year experience. Gut 1999; 45 Suppl 3: A94Google Scholar
  30. 30.
    Popovic N, Bulajic M, Glisic M, et al. Comparison of two triple therapies (ranitidine plus amoxicilline plus tinidazole v/s omeprazole plus amoxicilline plus tinidazol) in patients with Helicobacter pylori positive duodenal ulcer. Gut 1997; 41 Suppl 1: A102Google Scholar
  31. 31.
    Ruszniewski P, Lamouliatte H, Flejou JF, et al. Evaluation of short-term ranitidine vs omeprazole triple therapy regimens for eradication of Helicobacter pylori (Hp) in duodenal ulcer (DU) patients (pts). Gut 1997; 41 Suppl 1: A94Google Scholar
  32. 32.
    Sacca N, De Medici A, Rodino S, et al. Duodenal ulcer Helicobacter pylori (HP) positive: therapy with ranitidine (R) + clarithromicine (C) + metronidazole (M) versus omeprazole (O) + clarithromicine + metronidazole. Gut 1996; 39 Suppl 2: A34Google Scholar
  33. 33.
    Savarino V, Zentilin P, Bisso G, et al. Head-to-head comparison of 1-week triple regimens combining ranitidine or omeprazole with two antibiotics to eradicate Helicobacter pylori. Aliment Pharmacol Ther 1999; 13: 643–9PubMedCrossRefGoogle Scholar
  34. 34.
    Shcherbakov PL, Filin VA, Volkov IA, et al. A randomized comparison of triple therapy Helicobacter pylori eradication regimens in children with peptic ulcers. J Int Med Res 2001; 29: 147–53PubMedGoogle Scholar
  35. 35.
    Spadaccini A, De Fanis C, Sciampa G, et al. Omeprazole versus ranitidine: short-term triple-therapy in patients with Helicobacter pylori-positive duodenal ulcers. Aliment Pharmacol Ther 1996; 10: 829–31PubMedCrossRefGoogle Scholar
  36. 36.
    Tham TC, Collins JS, Molloy C, et al. Randomised controlled trial of ranitidine versus omeprazole in combination with antibiotics for eradication of Helicobacter pylori. Ulster Med J 1996; 65: 131–6PubMedGoogle Scholar
  37. 37.
    Treiber G, Ammon S, Klotz U. Age-dependent eradication of Helicobacter pylori with dual therapy. Aliment Pharmacol Ther 1997; 11: 711–8PubMedCrossRefGoogle Scholar
  38. 38.
    Peterson WL. The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11 Suppl 1: 21–5PubMedCrossRefGoogle Scholar
  39. 39.
    Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000; 38: 243–70PubMedCrossRefGoogle Scholar
  40. 40.
    van Zanten SJ, Goldie J, Hollingsworth J, et al. Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori. J Clin Pathol 1992; 45: 225–7PubMedCrossRefGoogle Scholar
  41. 41.
    Meyer-Rosberg K, Scott DR, Rex D, et al. The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology 1996; 111: 886–900PubMedCrossRefGoogle Scholar
  42. 42.
    Alarcon T, Domingo D, Sanchez I, et al. In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1996; 15: 937–40PubMedCrossRefGoogle Scholar
  43. 43.
    Cederbrant G, Kahlmeter G, Schalen C, et al. Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori. J Antimicrob Chemother 1994; 34: 1025–9PubMedCrossRefGoogle Scholar
  44. 44.
    Grayson ML, Eliopoulos GM, Ferraro MJ, et al. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989; 8: 888–9PubMedCrossRefGoogle Scholar
  45. 45.
    Goddard AF, Jessa MJ, Barrett DA, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice [see comments]. Gastroenterology 1996; 111: 358–67PubMedCrossRefGoogle Scholar
  46. 46.
    Labenz J, Beker JA, Dekker CP, et al. Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dmual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. Aliment Pharmacol Ther 1997; 11: 515–22Google Scholar
  47. 47.
    Miehlke S, Mannes GA, Lehn N, et al. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 1997; 11: 323–9PubMedCrossRefGoogle Scholar
  48. 48.
    Pommerien W, Schultze V, Braden B, et al. Dose-response of omeprazole combined with amoxycillin on duodenal ulcer healing and eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996; 10: 303–8PubMedCrossRefGoogle Scholar
  49. 49.
    Bayerdorffer E, Miehlke S, Mannes GA, et al. Doubleblind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995; 108: 1412–7PubMedCrossRefGoogle Scholar
  50. 50.
    Labenz J, Stolte M, Blum AL, et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995; 37: 39–43PubMedCrossRefGoogle Scholar
  51. 51.
    Sjostedt S, Sagar M, Lindberg G, et al. Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin [see comments]. Scand J Gastroenterol 1998; 33: 39–43PubMedCrossRefGoogle Scholar
  52. 52.
    Kleveland PM, Waldum HL, Brenna E, et al. Relationship between the efficacy of amoxicillin and intragastric pH for the treatment of Helicobacter pylori infection. Helicobacter 1997; 2: 144–8PubMedCrossRefGoogle Scholar
  53. 53.
    van der Hulst RW, Weel JF, Verheul SB, et al. Treatment of Helicobacter pylori infection with low or high dose omeprazole combined with amoxycillin and the effect of early retreatment. Aliment Pharmacol Ther 1996; 10: 165–71PubMedCrossRefGoogle Scholar
  54. 54.
    Malaty H, el-Zimaity HM, Genta RM, et al. High-dose proton pump inhibitor plus amoxycillin for the treatment or retreatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1996; 10: 1001–4PubMedCrossRefGoogle Scholar
  55. 55.
    Erah PO, Goddard AF, Barrett DA, et al. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997; 39: 5–12PubMedCrossRefGoogle Scholar
  56. 56.
    Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole [see comments]. Aliment Pharmacol Ther 1999; 13: 719–29PubMedCrossRefGoogle Scholar
  57. 57.
    Vallve M, Vergara M, Gisbert JP, et al. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther 2002; 16: 1149–56Google Scholar
  58. 58.
    Bardhan KD, Dillon J, Axon AT, et al. Triple therapy for Helicobacter pylori eradication: a comparison of panto-prazole once versus twice daily. Aliment Pharmacol Ther 2000; 14: 59–67PubMedCrossRefGoogle Scholar
  59. 59.
    Chiba N, Marshall CP. Omeprazole once or twice daily with clarithromycin and metronidazole for Helicobacter pylori. Can J Gastroenterol 2000; 14: 27–31PubMedGoogle Scholar
  60. 60.
    Megraud F, Boyanova L, Lamouliatte H. Activity of lansoprazole against Helicobacter pylori [Letter]. Lancet 1991; 337: 1486PubMedCrossRefGoogle Scholar
  61. 61.
    Alarcon T, Domingo D, Sanchez I, et al. In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1998; 17: 275–7PubMedGoogle Scholar
  62. 62.
    Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963–78PubMedCrossRefGoogle Scholar
  63. 63.
    Powell KU, Bell GD, Bowden AF, et al. Helicobacter pylori eradication therapy: a comparison between either omeprazole or ranitidine in combination with amoxycillin plus metronidazole. Br J Clin Res 1995; 6: 163–9Google Scholar
  64. 64.
    Rollan A, Giancaspero R, Acevedo C, et al. Treatment of Helicobacter pylori infection in patients with duodenal ulcer: a cost-benefit study. Rev Med Chil 2000; 128: 367–77PubMedGoogle Scholar
  65. 65.
    Gisbert JP. Lansoprazole: a review of its role in Helicobacter pylori eradication therapy. Rev Esp Enferm Dig 1999; 91: 133–43PubMedGoogle Scholar
  66. 66.
    Huber R, Kohl B, Sachs G, et al. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9: 363–78PubMedCrossRefGoogle Scholar
  67. 67.
    Fitton A, Wiseman L, Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51: 460–82PubMedCrossRefGoogle Scholar
  68. 68.
    Parsons ME. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Eur J Gastroenterol Hepatol 1996; 8 Suppl 1: S15–20PubMedCrossRefGoogle Scholar
  69. 69.
    Gisbert JP, Boixeda D, Martin de Argila C, et al. Role of pantoprazole in the eradicating treatment of Helicobacter pylori. Rev Clin Esp 1998; 198: 678–83PubMedGoogle Scholar
  70. 70.
    Thomson AB. Are the orally administered proton pump inhibitors equivalent? a comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole Curr Gastroenterol Rep 2000; 2: 482–93Google Scholar
  71. 71.
    Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000; 22: 266–80; discussion 265PubMedCrossRefGoogle Scholar
  72. 72.
    Jungnickel PW. Pantoprazole: a new proton pump inhibitor. Clin Ther 2000; 22: 1268–93PubMedCrossRefGoogle Scholar
  73. 73.
    Poole P. Pantoprazole. Am J Health Syst Pharm 2001; 58: 999–1008PubMedGoogle Scholar
  74. 74.
    Suerbaum S, Leying H, Klemm K, et al. Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori [Letter]. Eur J Clin Microbiol Infect Dis 1991; 10: 92–3PubMedCrossRefGoogle Scholar
  75. 75.
    Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter 1998; 3: 21–7PubMedCrossRefGoogle Scholar
  76. 76.
    Dattilo M, Figura N. Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors. J Clin Gastroenterol 1998; 27 Suppl 1: S163–9PubMedCrossRefGoogle Scholar
  77. 77.
    Hartmann M, Theiss U, Huber R, et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996; 10: 359–66PubMedCrossRefGoogle Scholar
  78. 78.
    Gisbert JP, Khorrami S, Calvet X, et al. Pantoprazole based therapies in Helicobacter pylori eradication: systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2004; 16: 89–99PubMedCrossRefGoogle Scholar
  79. 79.
    Unge P. What other regimens are under investigation to treat Helicobacter pylori infection? Gastroenterology 1997; 113: S131–48PubMedCrossRefGoogle Scholar
  80. 80.
    Pipkin GA, Williamson R, Wood JR. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1998; 12: 823–37PubMedCrossRefGoogle Scholar
  81. 81.
    Laheij RJ, Rossum LG, Jansen JB, et al. Evaluation of treatment regimens to cure Helicobacter pylori infection — a meta-analysis. Aliment Pharmacol Ther 1999; 13: 857–64PubMedCrossRefGoogle Scholar
  82. 82.
    Gisbert JP, Carpio D, Marcos S, et al. One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2000; 12: 489–95PubMedCrossRefGoogle Scholar
  83. 83.
    Svoboda P, Kantorova I, Ochmann J, et al. Pantoprazole-based dual and triple therapy for the eradication of Helicobacter pylori infection: a randomized controlled trial. Hepatogastroenterology 1997; 44: 886–90PubMedGoogle Scholar
  84. 84.
    Adamek RJ, Bethke TD. Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group. Am J Gastroenterol 1998; 93: 1919–24Google Scholar
  85. 85.
    Adamek RJ, Suerbaum S, Pfaffenbach B, et al. Primary and acquired Helicobacter pylori resistance to clarithro-mycin, metronidazole, and amoxicillin —influence on treatment outcome. Am J Gastroenterol 1998; 93: 386–9PubMedGoogle Scholar
  86. 86.
    Dehesa M, Larisch J, Di Silvio M, et al. Comparison of three seven days pantoprazole (panto) based Helicobacter pylori (Hp) eradication schemes in a Mexican population with highly metronidazole (met) resistant Hp strains [Abstract]. Gastroenterology 1998; 114: A288CrossRefGoogle Scholar
  87. 87.
    Lamouliatte H, Samoyeau R, De Mascarel A, et al. Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1999; 13: 1523–30PubMedCrossRefGoogle Scholar
  88. 88.
    Adamek RJ, Szymanski C, Pfaffenbach B. Pantoprazole versus omeprazole in one-week low-dose triple therapy for cure of H. pylori infection. Am J Gastroenterol 1997; 92: 1949–50Google Scholar
  89. 89.
    Cammarota G, Papa A, Cianci R, et al. Three-day anti-biotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study. Eur J Gastroenterol Hepatol 1999; 11: 247–50PubMedCrossRefGoogle Scholar
  90. 90.
    Catalano F, Branciforte G, Catanzaro R, et al. Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. Helicobacter 1999; 4: 178–84PubMedCrossRefGoogle Scholar
  91. 91.
    Catalano F, Catanzaro R, Branciforte G, et al. Five-day triple therapy in Helicobacter pylori-positive duodenal ulcer: an eighteen-month follow-up. J Clin Gastroenterol 2000; 31: 130–6PubMedCrossRefGoogle Scholar
  92. 92.
    Dominguez-Martin A, Dominguez-Muñoz A, Muñoz S, et al. Efficacy of six days triple therapy with pantoprazole plus clarithromycin and amoxycillin versus omeprazole plus clarithromycin and amoxycillin for H. pylori eradication [Abstract]. Gastroenterology 1998; 114: A107CrossRefGoogle Scholar
  93. 93.
    Rinaldi V, Zullo A, De Francesco V, et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther 1999; 13: 163–8PubMedCrossRefGoogle Scholar
  94. 94.
    Salces I, Soto S, Diaz-Tasende J, et al. Estudio compar-ativo de 3 pautas de erradicación de H. pylori [Abstract]. Rev Esp Enferm Dig 2001; 93 Suppl I: 156Google Scholar
  95. 95.
    Prakash A, Faulds D. Rabeprazole. Drugs 1998; 55: 261–7PubMedCrossRefGoogle Scholar
  96. 96.
    Langtry HD, Markham A. Rabeprazole: a review of its use in acid-related gastrointestinal disorders. Drugs 1999; 58: 725–42PubMedCrossRefGoogle Scholar
  97. 97.
    Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 1999; 13 Suppl 3: 3–10PubMedCrossRefGoogle Scholar
  98. 98.
    Carswell CI, Goa KL. Rabeprazole: an update of its use in acid-related disorders. Drugs 2001; 61: 2327–56PubMedCrossRefGoogle Scholar
  99. 99.
    Williams MP, Sercombe J, Hamilton MI, et al. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 1079–89PubMedCrossRefGoogle Scholar
  100. 100.
    Ohning GV, Barbuti RC, Kovacs TO, et al. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 701–8PubMedCrossRefGoogle Scholar
  101. 101.
    Hirai M, Azuma T, Ito S, et al. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterol 1995; 30: 461–4PubMedCrossRefGoogle Scholar
  102. 102.
    Kawakami Y, Akahane T, Yamaguchi M, et al. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 2000; 44: 458–61PubMedCrossRefGoogle Scholar
  103. 103.
    Fujioka T, Kawasaki H, Su WW, et al. In vitro anti-microbial activity against H. pylori and clinical efficacy of various drugs. Nippon Rinsho 1993; 51: 3255–60PubMedGoogle Scholar
  104. 104.
    Fujiyama K, Fujioka T, Kodama R, et al. Effect of E3810, a novel proton pump inhibitor, against Helicobacter pylori [Abstract]. Am J Gastroenterol 1994; 89: 1371Google Scholar
  105. 105.
    Tsutsui N, Taneike I, Ohara T, et al. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori. Antimicrob Agents Chemother 2000; 44: 3069–73PubMedCrossRefGoogle Scholar
  106. 106.
    Ohara T, Goshi S, Taneike I, et al. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter 2001; 6: 125–9PubMedCrossRefGoogle Scholar
  107. 107.
    Lopez-Brea M, Domingo D, Martinez M, et al. In vitro activity of rabeprazole compared with omeprazole in Helicobacter pylori clinical isolates [Abstract]. Gut 2001; 49 Suppl II: A7Google Scholar
  108. 108.
    Bosques-Padilla FJ, Tijerina-Menchaca R, Maldonado-Garza HJ, et al. Bacteriostatic and bactericidal activity of rabeprazole in Helicobacter pylori clinical isolates [Abstract]. Gut 2002; 51 Suppl II: A100Google Scholar
  109. 109.
    Tsuchiya M, Imamura L, Park JB, et al. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull 1995; 18: 1053–6PubMedCrossRefGoogle Scholar
  110. 110.
    Park JB, Imamura L, Kobashi K. Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole. Biol Pharm Bull 1996; 19: 182–7PubMedCrossRefGoogle Scholar
  111. 111.
    Cloud ML, Enas N, Humphries TJ, et al. Rabeprazole in treatment of acid peptic diseases: results of three placebocontrolled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. Dig Dis Sci 1998; 43: 993–1000PubMedCrossRefGoogle Scholar
  112. 112.
    Gisbert JP, Khorrami S, Calvet X, et al. Systematic review: rabeprazole-based therapies in Helicobacter pylori eradication. Aliment Pharmacol Ther 2003; 17: 751–64PubMedCrossRefGoogle Scholar
  113. 113.
    Dojo M, Azuma T, Saito T, et al. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig Liver Dis 2001; 33: 671–5PubMedCrossRefGoogle Scholar
  114. 114.
    Inaba T, Mizuno M, Kawai K, et al. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J Gastroenterol Hepatol 2002; 17: 748–53PubMedCrossRefGoogle Scholar
  115. 115.
    Kawabata H, Khayakumo T, Nakajima M, et al. Effects of different PPIs, genetic difference in CYP2C19 status and antibiotic susceptibility patterns on the cure rate of H. pylori infection by one-week triple therapy: results of a randomized trial in Japan [Abstract]. Gastroenterology 2001; 120 Suppl 1: 2964Google Scholar
  116. 116.
    Kuwayama H, Takahashi M, Takada H, et al. Comparison of standard dose rabeprazole and double dose omeprazole in PPI-based triple therapy for Helicobacter pylori infection — a randomized clinical trial [Abstract]. Gastroenterology 2001; 120 Suppl 1: 2970Google Scholar
  117. 117.
    Miki I, Aoyama N, Sakai T, et al. The key to successful eradication of H. pylori, using lansoprazole or rabeprazole based triple therapy, is clarithromycin resistance, not CYP2C19 polymorphism [Abstract]. Gastroenterology 2001; 120 Suppl 1: 2984Google Scholar
  118. 118.
    Miwa H, Ohkura R, Murai T, et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection —comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999; 13: 741–6PubMedCrossRefGoogle Scholar
  119. 119.
    Miwa H, Yamada T, Sato K, et al. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. Dig Dis Sci 2000; 45: 77–82PubMedCrossRefGoogle Scholar
  120. 120.
    Miyoshi M, Mizuno M, Ishiki K, et al. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J Gastroenterol Hepatol 2001; 16: 723–8PubMedCrossRefGoogle Scholar
  121. 121.
    Murakami K, Fujioka T, Okimoto T, et al. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents 2002; 19: 67–70PubMedCrossRefGoogle Scholar
  122. 122.
    Vakil N, Schwartz H.J., Lanza FL, et al. A prospective, controlled, randomized trial of 3-, 7-, and 10-day rabeprazole-based triple therapy for H. pylori eradication in the USA [Abstract]. Gastroenterology 2002; 122: 551Google Scholar
  123. 123.
    Wong BC, Wong WM, Yee YK, et al. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15: 1959–65Google Scholar
  124. 124.
    Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 1027–30PubMedGoogle Scholar
  125. 125.
    Furuta T, Shirai N, Takashima M, et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001; 11: 341–8PubMedCrossRefGoogle Scholar
  126. 126.
    Yasuda S, Horai Y, Tomono Y, et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 1995; 58: 143–54PubMedCrossRefGoogle Scholar
  127. 127.
    VandenBranden M, Ring BJ, Binkley SN, et al. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 1996; 6: 81–91CrossRefGoogle Scholar
  128. 128.
    Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors —emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13 Suppl 3: 27–36PubMedCrossRefGoogle Scholar
  129. 129.
    Uchihara M, Izumi N, Noguchi O, et al. Cytochrome P450 2C19 (CYP2C19) genotype status is not associated with cure rates of dual therapy with rabeprazole and amoxicillin for Helicobacter pylori [Abstract]. Gastroenterology 2001; 120 Suppl 1: 2985Google Scholar
  130. 130.
    Kawamura N, Sugiyama T, Saito M, et al. Eradication efficacy of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori does not depend on P450 genotype of the patients [Abstract]. Gut 2000; 47 Suppl I: A105Google Scholar
  131. 131.
    Hokari K, Sugiyama T, Kato M, et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment Pharmacol Ther 2001; 15: 1479–84PubMedCrossRefGoogle Scholar
  132. 132.
    Kawai T, Ogua K, Kudou T, et al. Comparison of dual therapy of rabeprazole plus amoxicillin and triple therapy for cure of Helicobacter pylori infection [Abstract]. Gastroenterology 2001; 120 Suppl 1: 2971Google Scholar
  133. 133.
    Spencer CM, Faulds D. Esomeprazole. Drugs 2000; 60: 321–9; discussion 330-1PubMedCrossRefGoogle Scholar
  134. 134.
    Scott LJ, Dunn CJ, Mallarkey G, et al. Esomeprazole: a review of its use in the management of acid-related disorders. Drugs 2002; 62: 1503–38PubMedCrossRefGoogle Scholar
  135. 135.
    Johnson TJ, Hedge DD. Esomeprazole: a clinical review. Am J Health Syst Pharm 2002; 59: 1333–9PubMedGoogle Scholar
  136. 136.
    Johnson DA. Review of esomeprazole in the treatment of acid disorders. Expert Opin Pharmacother 2003; 4: 253–64PubMedCrossRefGoogle Scholar
  137. 137.
    Kale-Pradhan PB, Landry HK, Sypula WT. Esomeprazole for acid peptic disorders. Ann Pharmacother 2002; 36: 655–63PubMedCrossRefGoogle Scholar
  138. 138.
    Miner PB Jr, atz PO, Chen Y, et al. Esomeprazole 40 mg provides more effective intragastric acid suppression at steady state than standard doses of other proton pump inhibitors. Gastroenterology 2003; 124 Suppl 1: 232ACrossRefGoogle Scholar
  139. 139.
    Gatta L, Perna F, Figura N, et al. Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori. J Antimicrob Chemother 2003; 51: 439–42PubMedCrossRefGoogle Scholar
  140. 140.
    Gisbert JP, Pajares JM. Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis. Dig Liver Dis 2004; 36: 253–9PubMedCrossRefGoogle Scholar
  141. 141.
    Laine L, Fennerty MB, Osato M, et al. Esomeprazolebased Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol 2000; 95: 3393–8PubMedCrossRefGoogle Scholar
  142. 142.
    Tulassay Z, Kryszewski A, Dite P, et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol 2001; 13: 1457–65PubMedCrossRefGoogle Scholar
  143. 143.
    Vasil’ev Iu V, Kas’ianenko VI. Efficacy of the one week treatment with esomeprazole (nexium), clarythromycin, and amoxycillin of duodenal ulcer associated with Helicobacter pylori. Eksp Klin Gastroenterol 2002; 102: 47–51Google Scholar
  144. 144.
    Veldhuyzen Van Zanten S, Lauritsen K, Delchier JC, et al. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000; 14: 1605–11CrossRefGoogle Scholar
  145. 145.
    Veldhuyzen Van Zanten S, Machado S, Lee J. One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 1381–7CrossRefGoogle Scholar
  146. 146.
    Laine L. Review article: esomeprazole in the treatment of Helicobacter pylori. Aliment Pharmacol Ther 2002; 16 Suppl 4: 115–8PubMedCrossRefGoogle Scholar
  147. 147.
    Miehlke S, Ebert S, Kirsch C, et al. One-week triple therapy with esomeprazole, clarithromycin and metronidazole is highly effective in eradicating Helicobater pylori in the absence of antimicrobial resistance — a prospective randomized multicenter trial. Gastroenterology 2003; 124 Suppl 1: M1493Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Gastroenterology Service‘La Princesa’ University HospitalMadridSpain

Personalised recommendations